Study on the expression of TRIM7 in peripheral blood mononuclear cells of patients with sepsis and its early diagnostic value

Mingfeng Lu†, Aiwen Ma†, Jianwei Liu, Wenzhen Zhou, Peng Cao, Tao Chu and Lu Fan*

Abstract

Background: The early diagnosis of sepsis is beneficial to put forward a reasonable clinical treatment plan as soon as possible. This study was to explore the expression of Tripartite Motif 7 (TRIM7) in peripheral blood mononuclear cells (PBMCs) of patients with sepsis and its diagnostic value.

Methods: This is a cross-sectional study. A total of 69 patients with infectious diseases were enrolled in the emergency room. They were divided into the sepsis group (34 cases) and the non-sepsis infection group (35 cases). There were 25 healthy subjects who were selected as the control group. The expression of TRIM7 in PBMCs was observed by immunofluorescence staining. The correlation between the expression of TRIM7 mRNA and acute physiology and chronic health evaluation II (APACHE II) score, sequential organ failure assessment (SOFA) score, white blood cell (WBC), C-reactive protein (CRP), procalcitonin (PCT), tumor necrosis factor (TNF)-α and interleukin (IL)-6 was discussed. The receiver operating characteristic (ROC) curve was utilized for evaluating the value of TRIM7 expression for the early diagnosis of sepsis.

Results: The fluorescence intensity representing the expression level of TRIM7 in PBMCs of patients in the sepsis group was the lowest among three groups. The TRIM7 mRNA expression in PBMCs of the sepsis group was greatly decreased in comparison with that of the non-sepsis infection group and control group ($P < 0.05$). Spearman correlation analysis indicated that TRIM7 mRNA expression was negatively correlated with APACHE II score, SOFA score, WBC, CRP, PCT, TNF-α and IL-6. ROC curve analysis revealed that the area under curve (AUC) of TRIM7 mRNA expression in PBMCs for the diagnosis of sepsis was 0.798, with a 95% confidence interval of 0.691-0.905, a sensitivity of 73.5%, and a specificity of 77.1%.

Conclusion: The expression of TRIM7 in PBMCs of patients with sepsis is significantly down-regulated, which has certain clinical value for early diagnosis of sepsis.

Keywords: TRIM7, PBMCs, Sepsis, Diagnosis

Background

Sepsis is a life-threatening organ dysfunction caused by uncontrolled response to infection [1]. Annually, more than 19 million sepsis cases are reported in the world, of which about 6 million patients die, and about 3 million people survive with different degrees of dysfunction.
Patients with potential autoimmune diseases; clinical data. The exclusion criteria: (1) Patients with met the diagnostic criteria of sepsis [1]; (2) Patients who were treated with antibiotics within 1 month before enrollment; (2) Patients who had bacterial or viral infection within 1 month before enrollment.

Collection of clinical data
The baseline clinical data at admission were recorded, including age, sex, comorbid conditions, and infection site. Acute physiology and chronic health evaluation II (APACHE II) and sequential organ failure assessment (SOFA) scores were performed on all subjects. On the day of admission, a blood routine examination was performed by the automatic analyzer, WBC count was recorded, CRP concentration in plasma was detected by rate turbidimetry, and procalcitonin (PCT) level was detected by chemiluminescence.

Detection of TNF-α and IL-6 in plasma
The concentration of TNF-α in plasma was detected by the human cytokine ELISA kit (ehc103a.96, NeoBiOscience), and the concentration of IL-6 in plasma was detected by the human cytokine ELISA kit (ehc007.96, NeoBiOscience). All samples were measured twice to obtain the mean value.

The expression of TRIM7 in PBMCs
The separation of PBMCs
When patients were admitted to the hospital, a total of 5 mL venous blood was drawn and placed into anticoagulation tubes. PBMCs were extracted from the blood sample by gradient centrifugation with Ficoll Paque (71101900-EH, GE Healthcare Bio-Sciences). The cells were re-suspended in PBS solution for immunofluorescence and Real-time Quantitative PCR (qPCR) detection of TRIM7.

The expression of TRIM7 protein in PBMCs detected by immunofluorescence
The concentration of PBMCs suspension was adjusted to $5 \times 10^6$/mL with PBS, and 20 µL of PBMCs suspension for each sample was dripped onto glass slides, fixed with 4% paraformaldehyde, and sealed with 0.1% TritonX-100 and 1% bovine serum albumin (BSA). Rabbit polyclonal antibody to TRIM7 (LS-C146201, LifeSpan Biosciences) was used for the primary antibody, Goat anti-Rabbit IgG-FITC antibody (HA1004, Hangzhou HuaAn Biotechnology) was used for the secondary antibody, and 4′,6-diamidino-2-phenylindole (DAPI) staining solution (C1002, Beyotime) was used for staining cell nucleus. After sealing by Prolong, the slides were observed and photographed under a laser confocal fluorescence microscope (LSM710, Zeiss). We used ImageJ software to analyze the brightness of the
cells in the immunofluorescence maps, and randomly selected 20 cells in each group for quantitative detection and took their mean values for comparison.

**Detection of the expression level of TRIM7 mRNA**

The TRIM7 mRNA in PBMCs was isolated from the same sample for the fluorescence experiment of TRIM7 protein. RNA was extracted from PBMCs with the RNA extraction kit (CW0584S, cwbio) and eluted with 30 µL elusion buffer, which is dedicated for RNA extraction. To prevent RNA degradation, the RNA extraction experiment was carried out immediately after separation of PBMCs. All equipment including pipetting tips, EP tubes and experimental reagents were RNase-free. The gloves were changed in time during the experiment. cDNA was produced from RNA through reverse transcription. Real-time PCR was performed on Roche Light Cycler 2.0 fluorescent quantitative PCR instrument by employing the SYBR Green Real-time PCR Master Mix kit (E096-01A, Novoprotein). The data were processed with Light Cycle Software 4.1, and the Ct value of the target genes was standardized with the Ct value of human GAPDH. The $2^{-\Delta\Delta C_{t}}$ method was used to calculate the variation of the amplification multiple of the sample. The quantitative primer sequences were as follows:

- **GAPDH** sense 5’GGAGCGAGATCCCTCCAA AAT 3’,
- **GAPDH** antisense 5’GGCTGTTGTCATACCTCT CATGG 3’;
- **TRIM7** sense 5’TCCATGTCCAAGTCCCTCCTCC 3’,
- **TRIM7** antisense 5’GGCCAGTTCTCATTCTG CT 3’.

**Statistical methods**

Statistical Product and Service Solutions (SPSS) 26.0 was utilized for statistical analysis. Continuous variables with normal distribution were presented as mean ± SD. Variables with abnormal distribution were presented as median (Inter quartile range, IQR). ANOVA or Kruskal Wallis was employed for analyzing the comparison among the three groups. The chi-square test or Fisher’s exact test was used to compare categorical variables. The spearman analysis method was used for correlation analysis. The ROC curve was applied for evaluating the early diagnostic value of TRIM7 expression in PBMCs in sepsis. All statistics were two-sided, only a $p$-value of 0.05 or less was considered statistically significant.

**Results**

**Demographic characteristics and clinical parameters of patients in each group**

In this study, 34 patients in sepsis group, 35 patients in non-septic infection group and 25 healthy controls were collected. The pathogens of all patients infected in the experiment were considered as bacteria. There was no significant difference in age, sex, comorbid conditions, or infection site among the three groups ($p > 0.05$). Organ function scores including APACHE II, SOFA scores, and inflammatory indexes including CRP, PCT, TNF-α and IL-6 were significantly different among the three groups. These parameters of the sepsis group were considerably elevated in comparison with those of the non-septic infection group and control group ($p < 0.05$); WBC levels in the sepsis group and non-septic infection group were higher than those in control group ($p < 0.05$), but no notable difference was observed between the sepsis group and the non-septic infection group (Table 1).

**The expression level of TRIM7 protein in PBMCs of each group detected by immunofluorescence**

DAPI was used to label the nucleus (blue), fluorescein isothiocyanate (FITC) was used to label TRIM7 protein (green), and a laser confocal microscope was employed for fluorescence detection. The outcomes revealed that the positive TRIM7 protein expression was mainly located in the nucleus, showing green fluorescence. The green fluorescence intensity representing the expression level of TRIM7 in PBMCs of patients in the sepsis group was the lowest among three groups. The fluorescence intensity of TRIM7 in non-septic infection group was also down-regulated than that of the control group (Fig. 1).

**The expression level of TRIM7 mRNA in PBMCs of each group and its correlation with inflammatory indexes and organ function scores**

The expression of TRIM7 mRNA in PBMCs of the non-septic infection group was substantially down-regulated than that of control group ($p < 0.05$). The expression of TRIM7 mRNA in PBMCs of the sepsis group was significantly reduced to the lowest level comparing to that of non-septic infection group and control group ($p < 0.05$) (Table 1). Spearman correlation analysis highlighted that the expression level of TRIM7 mRNA in PBMCs was negatively associated with APACHE II score, SOFA score, WBC, CRP, PCT, TNF-α, and IL-6 (Table 2).
Diagnostic value of the expression level of TRIM7 in PBMCs for sepsis

ROC curve analysis revealed that the AUC of TRIM7 mRNA expression in PBMCs for the diagnosis of sepsis was 0.798, with a 95% confidence interval of 0.691-0.905, a sensitivity of 73.5%, and a specificity of 77.1% (Table 3). Figure 2 showed the comparison of the diagnostic value for sepsis between TRIM7 and other commonly used clinical indicators.

Discussion

With the rapid development of molecular biology and laboratory testing technology, increasing researches have been devoted to explore the new biomarkers in diagnosis and severity evaluation for sepsis [12]. Toll-like receptors (TLRs) play an important role in sepsis [13], among which TLR4 has been widely studied and considered as a key molecule in the innate immune system, participating in the occurrence and development of sepsis [14]. TLR4 is a crucial transmembrane receptor that can mediate both the inflammatory response to exogenous ligands like lipopolysaccharide (LPS) and the endogenous danger signals generated at the time of inflammatory response [15]. In LPS-induced sepsis, activation of TLR4 causes downstream NF-κB and MAPKs pathways to be activated in a MyD88-dependent manner, thereby enhancing pro-inflammatory cytokines including TNF-α and IL-6 [16]. Many proteins that regulate the TLR4 pathway have come to the attention of researchers. On one hand, the expression level of these protein molecules is related to Table 1

| Characteristic | Health control | Non-septic infection | Sepsis | p value |
|---------------|----------------|----------------------|--------|---------|
| Demographics  |                |                      |        |         |
| N             | 25             | 35                   | 34     |         |
| Age (years)   | 63.3 ± 14.67   | 68.6 ± 14.22         | 68.2 ± 13.14 | 0.297    |
| Gender, male (%) | 14    | 15                    | 20     | 0.374    |
| Comorbid conditions N (%) |     |                      |        |         |
| Diabetes mellitus | 6       | 10                   | 12     | 0.632    |
| Cardiac insufficiency | 5     | 15                    | 15     | 0.114    |
| Chronic obstructive pulmonary disease | 1 | 4                     | 3      | 0.594    |
| Chronic renal insufficiency | 2 | 2                     | 3      | 0.879    |
| Chronic liver disease | 1   | 2                     | 3      | 0.740    |
| Malignancy     | 3              | 1                    | 5      | 0.220    |
| Site of infection N (%) |     |                      |        |         |
| Respiratory    | 10             | 15                   |        | 0.209    |
| Urinary        | 9              | 8                    |        | 0.833    |
| Abdominal      | 7              | 8                    |        | 0.722    |
| Musculoskeletal, skin and soft tissue | 5 | 5                     |        | 0.950    |
| Bloodstream    | 7              | 6                    |        | 0.803    |
| Others         | 3              | 1                    |        | 0.317    |
| Organ function indices and inflammatory biomarkers | | | | |
| APACHE II      | 5 (2, 6)       | 9 (7, 12)a           | 20 (14, 25)ab | 0.000    |
| SOFA           | 0 (0, 0)       | 2 (1, 3)a            | 7 (6, 10)ab | 0.000    |
| WBC (10^9/L)   | 6.7 ± 2.72     | 13.7 ± 4.49a         | 142 ± 6.77a | 0.000    |
| CRP (mg/L)     | 2.6 ± 3.14     | 64.2 ± 42.37a        | 114 ± 78.10b | 0.000    |
| PCT (µg/L)     | 0.16 (0.05, 0.26) | 1.19 (0.12, 8.21)ya | 10.10 (3.80, 62.36)ab | 0.000    |
| TNF-α (ng/L)   | 24.34 (19.17, 43.09) | 36.98 (25.12, 68.23)ya | 67.48 (28.95, 92.29)ab | 0.000    |
| IL-6 (ng/L)    | 13.30 (6.90, 35.64) | 43.05 (23.45, 81.90)ya | 115.33 (60.78, 246.31)ab | 0.000    |
| TRIM7 mRNA (2^−ΔΔCt) | 8.06 (5.28, 13.38) | 2.86 (1.88, 3.97)ya | 1.10 (0.83, 2.00)ab | 0.000    |

Continuous variables with normal distribution were presented as mean ± SD. Variables with abnormal distribution were presented as median (IQR). ANOVA or Kruskal Wallis was employed for analyzing the comparison among the three groups. The chi-square test or Fisher’s exact test was used to compare categorical variables.

APACHE II acute physiology and chronic health evaluation II, SOFA sequential organ failure assessment, WBC white blood cell, CRP C-reactive protein, PCT procalcitonin, TNF-α tumor necrosis factor-α, IL-6 interleukin-6

a Compared to control group
b Compared to non-septic group
Fig. 1 The expression level of TRIM7 protein in PBMCs of each group detected by immunofluorescence. A Immunofluorescence images showing staining of PBMCs of individuals from sepsis group, non-septic infection group and health control group with DAPI (blue), or antibodies against TRIM7 (green). Images were taken at the magnification of 400. Scale bar represents 20 μm. B The quantitative analysis with ImageJ software revealed that the expression level of TRIM7 in PBMCs of patients in the sepsis group was the lowest among three groups. The fluorescence intensity of TRIM7 in non-septic infection group was also down-regulated than that of the control group. The expression level of DAPI in PBMCs among the three groups showed no significant difference.
the TLR4-activated inflammatory response, which can be used to evaluate the severity of the infection and predict the occurrence of sepsis [17–19]. On the other hand, these protein molecules may become potential targets for the early diagnosis and treatment of sepsis [20, 21].

As an E3 ubiquitin ligase, TRIM7 participates in some important biological processes, such as glycogen metabolism and tumor cell proliferation [22, 23]. Studies have suggested that TRIM7 may play an antiviral role against norovirus [24]. Our previous research also found that TRIM7 can participate in the regulation of innate immunity through the TLR4 signaling pathway, which positively regulates the activation of downstream NF-κB and MAPKs pathways. Our previous cell experiments showed that the expression level of TRIM7 was down-regulated immediately in mouse peritoneal macrophages after LPS stimulation, then recovered to the initial level after 24 h [10]. According to the above research results, the expression level of TRIM7 may reflect the severity of infectious diseases and may predict the occurrence of sepsis in the early stage of infection.

PBMCs can contact with pathogens and interact with infected cells through secreted signal molecules. They have a recognized role in monitoring infection [25]. For example, Zhang et al. discovered that the decreased expression of miR-23b in PBMCs of patients with sepsis was negatively correlated with the inflammatory response, which could reduce the release of inflammatory cytokines stimulated by LPS [26]. Our research found that the expression level of TRIM7 in PBMCs of patients with non-septic-infection was lower than that of normal controls, while the expression level of TRIM7 in PBMCs of patients with sepsis was lower than that of patients with non-septic-infection. At the same time, the expression of TRIM7 was negatively correlated with disease severity scores including SOFA [27], APACHE II score [28], and inflammation-related indicators including WBC, CRP, PCT, TNF-α, and IL-6. The expression of TRIM7 in PBMCs of individuals with infection is closely related to its biological role in affecting inflammatory response through regulating the TLR4 pathway, and its change trend is consistent with the results of our previous cell experiments. The outcomes of the present research revealed that the reduced level of TRIM7 expression in PBMCs may indicate a more serious condition in infectious diseases. Intriguingly, our previous experiments have confirmed that overexpression of TRIM7 can activate NF-κB and MAPKs pathways, resulting in increased release of TNF-α, IL-6 and other inflammatory factors, thus aggravating the inflammatory response. Knockdown of TRIM7 can reduce the inflammatory response, suggesting that TRIM7 can positively regulate the inflammatory response after infection [10]. We assume that the down-regulation of TRIM7 expression in PBMCs of

Table 2  The correlation between TRIM7 mRNA expression and organ function scores, inflammatory indexes

| Related indexes | APACHE II | SOFA | WBC (10^9/L) | CRP (mg/L) | PCT (ng/L) | TNF-α (ng/L) | IL-6 (ng/L) |
|-----------------|-----------|------|--------------|------------|------------|--------------|-------------|
| r_s             | −0.699    | −0.609| −0.336       | −0.516     | −0.584     | −0.318       | −0.454      |
| p value         | 0.000     | 0.000| 0.001        | 0.000      | 0.000      | 0.002        | 0.000       |

The spearman analysis method was used for correlation analysis.

APACHE II acute physiology and chronic health evaluation II, SOFA sequential organ failure assessment, WBC white blood cell, CRP C-reactive protein, PCT procalcitonin, TNF-α tumor necrosis factor-α, IL-6 interleukin-6

Table 3  Areas under the curve of TRIM7 mRNA level and inflammatory parameters for determining sepsis

| Parameter      | Cut-off value | AUC  | Sensitivity | Specificity | p value | 95% CI          |
|----------------|---------------|------|-------------|-------------|---------|----------------|
| WBC (10^9/L)   | 14.105        | 0.541| 0.647       | 0.543       | 0.560   | 0.401 to 0.680 |
| CRP (mg/L)     | 74.955        | 0.676| 0.676       | 0.657       | 0.012   | 0.547 to 0.805 |
| PCT (µg/L)     | 3.680         | 0.772| 0.794       | 0.743       | 0.000   | 0.658 to 0.887 |
| TNF-α (ng/L)   | 49.512        | 0.647| 0.706       | 0.600       | 0.036   | 0.516 to 0.778 |
| IL-6 (ng/L)    | 47.250        | 0.729| 0.853       | 0.571       | 0.001   | 0.608 to 0.850 |
| TRIM7 (2^-△△Ct)| 1.829        | 0.798| 0.735       | 0.771       | 0.000   | 0.691 to 0.905 |

The ROC curve was applied for evaluating the early diagnostic value of TRIM7 expression and inflammatory parameters in PBMCs in sepsis.

AUC area under curve, CI confidence interval, WBC white blood cell, CRP C-reactive protein, PCT procalcitonin, TNF-α tumor necrosis factor-α, IL-6 interleukin-6
sepsis patients may be related to the host's self-defense after infection. The mechanism of the above phenomenon deserves further research.

Early identification and diagnosis of sepsis are conducive to the rapid development of a reasonable treatment plan, which is of great value in improving the prognosis of patients with sepsis. In the present research, we also assessed the diagnostic values of commonly used clinical indicators for sepsis. ROC curve analysis revealed that the diagnostic value of plasma WBC, CRP, and TNF-α for sepsis was dissatisfactory, while PCT and IL-6 were slightly better. The AUC of TRIM7 mRNA's level in PBMCs for the diagnosis of sepsis was 0.798, the sensitivity was 73.5%, and the specificity was 77.1%. As an early diagnostic index, it shows a good sensitivity while its specificity even exceeds PCT, which is commonly used in clinic. The good specificity may be attributed to that the detection object of TRIM7 expression is PBMCs, which directly participates in the immune reaction after pathogen infection [24]. In addition, our prior research also verified that TRIM7 can regulate the expression of inflammatory factors after infection through TLR4 pathway, which makes it an important molecular in the development of sepsis [10]. By comparing with other clinical indicators, we can see that TRIM7 mRNA level in PBMCs has certain advantages in the early diagnosis of sepsis.

**Conclusion**

In conclusion, the expression level of TRIM7 in PBMCs of patients with sepsis is significantly down-regulated, which has a certain value for early diagnosis of sepsis and can be used as a supplement to common infection markers in clinical work. Since the change of TRIM7 expression in cell experiments mainly occurs in the early stage of infection [10], early and dynamic monitoring is required to accurately evaluate the severity of infectious diseases and predict the development of sepsis. There are some limitations in this study. We have enrolled a small size of population, and only recorded the TRIM7 expression of patients in the early stage of admission. In the future, the sample size can be expanded and the patients can be dynamically monitored to verify the existing research results.

**Acknowledgements**

Not applicable.

**Author contributions**

ML conceived of the study. ML and LF designed the analysis and performed the experiments. ML and AM performed the analysis and wrote the first draft of the manuscript. All authors contributed to data collection, interpretation

![Fig. 2 ROC curves of the TRIM7 mRNA level in PBMCs and clinical indexes for sepsis diagnosis](image)
of the data and revision of the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the Municipal Society Development Project of Yangzhou City (YZ2020091), Peking Union Medical Foundation-Ruiyi Emergency Medical Research Fund (R2019024).

Availability of data and materials
All data generated or analyzed during this study were included in this manuscript.

Declarations

Ethics approval and consent to participate
This research was approved by the ethics committee of Northern Jiangsu People's Hospital (No. 2020KY-176). Written informed consent was obtained from individual or guardian participants. All methods were carried out in accordance with relevant guidelines and regulations.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 18 July 2022   Accepted: 14 November 2022

The authors declare that they have no competing interests.

Competing interests
Not applicable.

Consent for publication
Not applicable.

References

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.

2. Perner A, Cecconi M, Cronhjort M, Darmon M, Jakob SM, Pettilä V, van der Horst ICC. Expert statement for the management of hypovolemia in sepsis. Intensive Care Med. 2018;44(6):791–8.

3. Prescott HC, Angus DC. Post sepsis morbidity. JAMA. 2018;319(1):91.

4. Reinhart K, Daniels R, Kissoon N, Machado FR, Schachter RD, Finfer S. Recognizing sepsis as a global health priority—a WHO resolution. N Engl J Med. 2017;377(5):414–7.

5. Qu Z, Zhu Y, Wang M, Li W, Zhu B, Jiang L, Xi X. Prognosis and risk factors of sepsis patients in Chinese ICUs: a retrospective analysis of a cohort database. Shock. 2021;56(6):921–6.

6. De Oro N, Gauthreaux ME, Lamoureux J, Scott J. The use of procalcitonin as a sepsis marker in a community hospital. J Appl Lab Med. 2019;4:4.

7. Kobayashi T, Iwata S, Hirata A, Yamamoto M, Yoshimoto S. Rapid changes in serum IL-6 levels in preterm newborns with Gram-negative early-onset sepsis. Cytokine. 2021;138:155371.

8. Ebner P, Versteeg GA, Ikeda F. Ubiquitin enzymes in the regulation of immune responses. Crit Rev Biochem Mol Biol. 2017;52:425–60.

9. Wang Q, Huang L, Hong Z, Lv Z, Mao Z, Tang Y, Kong X, Li S, Cui Y, Liu H, Zhang L, Zhang X, Jiang L, Wang C, Zhou Q. The E3 ubiquitin ligase RNF18 facilitates the cGAS-mediated innate immune response. PLoS Pathog. 2017;13(3):e1006264.

10. Lu M, Zhu X, Yang Z, Zhang W, Sun Z, Ju Q, Chen X, Zhu J, Wang C. Nie S. E3 ubiquitin ligase tripartite motif 7 positively regulates the TLR4-mediated immune response via its E3 ligase domain in macrophages. Mol Immunol. 2019;109:126–33.

11. Winiszewski H, Despres C, Puyraveau M, Lagourette-Remois J, Montange D, Besch G, Flory SP, Chaignat C, Laborgo V, Veltorotti L, Clair AL, Capellier G, Vivet B, Pitoz G. β-Lactam dosing at the early phase of sepsis: performance of a pragmatic protocol for target concentration achievement in a prospective cohort study. J Crit Care. 2022;67:141–6.

12. Wang H, Huang J, Li W, He N, Kang L, He Z, Chen C. Identification of immune-related key genes as potential diagnostic biomarkers of sepsis in children. J Inflam Res. 2022;15:2441–59.

13. Li HR, Liu J, Zhang SL, Luo T, Wu F, Dong JH, Guo YJ, Zhao L. Corlinag ameliorates the extreme inflammatory status in sepsis through TLR4 signaling pathways. BMC Complement Altern Med. 2017;17(1):18.

14. Chandrafitia N, Tanadhavanant S, Seel S, Wilkrapich S, Wongsuvan G, Anypraprnt P, Sutuntorn P, Teenswattanassoon N, Jitrakul Y, Srisurat N, Chanmanee P, Mahavananuk W, Srisaram P, Phiphaprom S, Mokchai M, Anukunanchanai J, Wongratanacheewin S, Chatchotsakd P, Emom M, Peacock SJ. West TE. TLR4 genetic variation is associated with inflammatory responses in Gram-positive sepsis. Clin Microbiol Infect. 2017;23(1):47.e1–10.

15. Park BS, Lee JG. Recognition of lipopolysaccharide pattern by TLR4 complex. Exp Mol Med. 2013;45(1):e66.

16. Wang Z, Chen W, Li Y, Zhang S, Lou H, Lu X, Fan X. Reducing injection and its effective constituent luteloside protect against sepsis partly via inhibition of HMGB1/TLR4/NF-κB/MAPKs signaling pathways. J Ethnopharmacol. 2021;270:113783.

17. Na L, Ding H, Xing E, Zhang Y, Gao J, Liu B, Yu J, Zhao Y. The predictive value of microRNA-21 for sepsis risk and its correlation with disease severity, systemic inflammation, and 28-day mortality in sepsis patients. J Clin Lab Anal. 2020;34(3):e23103.

18. Xie Z, Guo Z, Liu J. Whey acidic protein/four-disulphide core domain 21 regulates sepsis pathogenesis in a mouse model and a macrophage cell line via the Stat3/Toll-like receptor 4 (TLR4) signaling pathway. Med Sci Monit. 2018;24:4054–63.

19. Kuzmic NN, Sivak KV, Chubarev NV, Porozyov YB, Savateeva-Lyubimova TN, Pen F. TLR4 signaling pathway modulators as potential therapeutics in inflammation and sepsis. Vaccines (Basel). 2017;5(4):34.

20. Loubaki L, Chabot D, Paré I, Drouin M, Bazin R. MIR-146A potentially promotes Il1g-mediated inhibition of TLR4 signaling in LPS-activated human monocytes. Immunol Lett. 2017;185:64–73.

21. Venancio TM, Machado RM, Castoldi A, Amano MT, Nunes VS, Quinto EC, Camara NO, Soriyan FG, Gazita PM. CETP lowers TLR4 expression which attenuates the inflammatory response induced by LPS and polymicrobial sepsis. Mediat Inflamm. 2016;2016:1784014.

22. Montori-Grau M, Pedreira-Casahuaga R, Boyer-Díaz Z, Lassot I, García-Martínez C, Orozco A, Cebrián J, Osono-Coniles O, Chacón MR, Vendrell JL, Vázquez-Carrera M, Desagher S, Jiménez-Chillarín JC, Gómez-fox AM. GNP1 E3 ubiquitin ligase is a novel player in regulating glycogen metabolism in skeletal muscle. Metabolism. 2018;83:177–87.

23. Zhu L, Qin C, Li T, Ma X, Qiu Y, Lin Y, Ma D, Qin Z, Sun C, Shen X, Zhao Y, Han L. The E3 ubiquitin ligase TRIM7 suppressed hepatocellular carcinoma progression by directly targeting src protein. Cell Death Differ. 2020;27(6):1819–31.

24. Orchard RC, Sullender ME, Dunlap BF, Balce DR, Doench JG, Virgin HW. Identification of aseptin genes in human cells using genom-wide CRISPR activation screening. J Virol. 2018;93(1):e011324-18.

25. Boldrick JC, Alizadeh AA, Diehn M, Botstein D, Staudt LM, Brown PO, Relman DA. Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci USA. 2002;99(2):972–7.

26. Zhang W, Lu F, Xie Y, Lin Y, Zhao T, Tao S, Lai Z, Wei N, Yang R, Shao Y, He J. mir-23b negatively regulates sepsis-induced inflammatory responses by targeting ADAM10 in human THP-1 monocytes. Mediat Inflamm. 2019;2019:5306541.

27. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Suter PM, Thijs LG. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related problems of the European Society of Intensive Care Medicine, Intensive Care Med. 1996;22(7):707–10.

28. Sungono V, Haryanto H, Soesilo TEB, Adisasmita AC, Syarif S, Lukito AA, Arfianti D, Mahavanakul W, Srisamang P, Phiphitaporn S, Mokchai M, Anukunanchanai J, Wongratanacheewin S, Chatchotsakd P, Emom M, Peacock SJ. West TE. TLR4 genetic variation is associated with inflammatory responses in Gram-positive sepsis. Clin Microbiol Infect. 2017;23(1):47.e1–10.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.